Response of a Nonmalignant Pleural Effusion to Bevacizumab

Authors:

Abstract
The potential role of vascular endothelial growth factor in malignant as well as nonmalignant pleural effusion1,2 prompted us to use bevacizumab, a monoclonal antibody against vascular endothelial growth factor, in a 68-year-old man with primary cardiac amyloidosis who had severe dyspnea and underwent repeated thoracenteses for pleural effusions. Cytologic assessments of the pleural fluid did not detect malignant cells. Primary amyloidosis had been diagnosed by myocardial biopsy four weeks previously, but there were no other manifestations of amyloidosis. At the time of the patient's admission, left ventricular function was moderately reduced (ejection fraction, 40 percent). A radiograph of the chest showed massive pleural effusion in the right hemithorax. The C-reactive protein level was markedly increased (27.2 mg per deciliter), but no inflammatory infiltrate was seen in the radiograph of the lung. Thoracentesis was unsuccessful because of the segmented nature of the effusion. Because of the elevated C-reactive protein level, we began broad-spectrum antibiotic treatment and gave the patient an intravenous diuretic. After five days, the C-reactive protein level was reduced, but the clinical condition, with severe dyspnea, and the chest radiograph remained unchanged. The patient was judged unable to undergo anesthesia for surgical intervention and pleurodesis.